Cartesian Therapeutics (NASDAQ:RNAC – Get Free Report) and Zai Lab (NASDAQ:ZLAB – Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, profitability, dividends, institutional ownership, valuation, analyst recommendations and earnings.
Analyst Ratings
This is a breakdown of recent recommendations and price targets for Cartesian Therapeutics and Zai Lab, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cartesian Therapeutics | 1 | 1 | 5 | 0 | 2.57 |
| Zai Lab | 1 | 1 | 4 | 1 | 2.71 |
Cartesian Therapeutics presently has a consensus target price of $32.60, suggesting a potential upside of 402.31%. Zai Lab has a consensus target price of $37.25, suggesting a potential upside of 68.78%. Given Cartesian Therapeutics’ higher probable upside, equities research analysts clearly believe Cartesian Therapeutics is more favorable than Zai Lab.
Volatility & Risk
Insider and Institutional Ownership
87.0% of Cartesian Therapeutics shares are owned by institutional investors. Comparatively, 41.6% of Zai Lab shares are owned by institutional investors. 37.2% of Cartesian Therapeutics shares are owned by company insiders. Comparatively, 4.9% of Zai Lab shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Earnings and Valuation
This table compares Cartesian Therapeutics and Zai Lab”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cartesian Therapeutics | $2.80 million | 70.12 | -$130.30 million | ($5.94) | -1.09 |
| Zai Lab | $460.16 million | 5.46 | -$175.54 million | ($1.71) | -12.91 |
Cartesian Therapeutics has higher earnings, but lower revenue than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Cartesian Therapeutics and Zai Lab’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cartesian Therapeutics | -8,550.65% | N/A | -29.84% |
| Zai Lab | -41.86% | -27.43% | -16.72% |
Summary
Cartesian Therapeutics beats Zai Lab on 8 of the 15 factors compared between the two stocks.
About Cartesian Therapeutics
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.
About Zai Lab
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China.
Receive News & Ratings for Cartesian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cartesian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
